FOXO4-DRI 10mg

Cellular Senescence Research | Senolytic Pathways | Healthy Ageing Research

Product Highlights

• 10mg per vial of FOXO4-DRI (subject to product specification)

• Investigated for potential senolytic activity in preclinical research

• Studied for its interaction with FOXO4 and p53 signalling pathways

• Research interest in cellular senescence and ageing-related processes

• Investigated for its potential to selectively affect certain senescent cells

• Supplied as a lyophilized powder, where specified by the manufacturer

• Research compound intended for laboratory investigation

What is FOXO4-DRI?

FOXO4-DRI is an experimental, cell-penetrating peptide designed to investigate the relationship between the transcription factor FOXO4 and the tumour-suppressor protein p53.

It has attracted scientific interest for its potential role in cellular senescence research, particularly its ability to influence the survival of certain senescent cells.

Senescent cells are cells that have permanently or persistently stopped dividing but remain metabolically active. Some can accumulate with age and contribute to inflammatory signalling through the senescence-associated secretory phenotype (SASP).

FOXO4-DRI has been studied as a potential senolytic compound, meaning a substance investigated for its ability to promote the elimination of senescent cells.

Preclinical research has explored its potential relevance to ageing biology, tissue function, cellular stress responses, and senescence-associated inflammation.

Research remains at an early stage, and its safety and effectiveness in humans have not been established.

How It Works

• Cellular Senescence Research: Investigated for its potential to influence the survival and elimination of certain senescent cells

• FOXO4–p53 Interaction: Designed to interfere with the interaction between FOXO4 and p53, proteins involved in cellular stress and survival signalling

• Senolytic Pathways: Studied for its ability to promote apoptosis (programmed cell death) in selected senescent cell populations under experimental conditions

• Healthy Ageing Research: Investigated in preclinical models exploring the biological consequences of senescent-cell accumulation

• Inflammatory Signalling: Research interest in whether removing certain senescent cells may influence SASP-associated inflammatory processes

• Tissue Function Research: Explored in laboratory and animal models examining tissue responses associated with cellular ageing

What You'll Receive

• 1x 10mg vial of FOXO4-DRI

• Lyophilized peptide powder, subject to the supplied product specification

• Research-grade product, with quality specifications provided by the supplier

• Securely packaged for shipping

Storage Instructions

• Store according to the manufacturer's validated storage specifications

• Protect from direct light and moisture

• Keep the vial securely sealed

• Avoid unnecessary temperature fluctuations

• Follow the batch-specific documentation for storage conditions and stability

Storage requirements may vary by formulation. Refrigerated or frozen storage should only be specified where supported by the manufacturer's stability data.

Purity & Quality

FOXO4-DRI is a specialised research peptide for laboratory investigation. Quality assessment may include:

• Peptide identity verification

• Purity analysis using appropriate analytical methods

• Batch consistency assessment

• Review of applicable certificates of analysis (COAs)

Product purity, manufacturing standards and quality-control claims should be supported by batch-specific testing documentation.

For laboratory research purposes only. FOXO4-DRI is an experimental peptide and is not approved for human use or for the diagnosis, treatment, cure or prevention of disease. Its safety and efficacy in humans have not been established.